Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
2.365 EUR | +1.07% | +4.65% | -9.73% |
Apr. 15 | Sanofi: progress in hematology trial | CF |
Apr. 15 | Innate Pharma: progress in hematology trial | CF |
Sales 2024 * | 46.84M 50.79M | Sales 2025 * | 74.41M 80.67M | Capitalization | 189M 205M |
---|---|---|---|---|---|
Net income 2024 * | -25M -27.11M | Net income 2025 * | -21M -22.77M | EV / Sales 2024 * | 2.64 x |
Net cash position 2024 * | 65.68M 71.22M | Net cash position 2025 * | 122M 132M | EV / Sales 2025 * | 0.91 x |
P/E ratio 2024 * |
-16.1
x | P/E ratio 2025 * |
3.87
x | Employees | 179 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.91% |
Latest transcript on Innate Pharma
1 day | +1.07% | ||
1 week | +4.65% | ||
Current month | +7.26% | ||
1 month | +9.49% | ||
3 months | +3.50% | ||
6 months | +2.83% | ||
Current year | -9.73% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Vivier
FOU | Founder | 60 | 99-09-22 |
Chief Executive Officer | 62 | 99-09-22 | |
Frederic Lombard
DFI | Director of Finance/CFO | 49 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 99-09-22 | |
Gilles Brisson
BRD | Director/Board Member | 72 | 07-06-25 |
Olivier Martinez
BRD | Director/Board Member | 54 | 10-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2.365 | +1.07% | 58 295 |
24-05-16 | 2.34 | -0.43% | 25,179 |
24-05-15 | 2.35 | +1.08% | 42,368 |
24-05-14 | 2.325 | +1.09% | 58,572 |
24-05-13 | 2.3 | +1.77% | 10,961 |
Real-time Euronext Paris, May 17, 2024 at 07:43 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.73% | 206M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.45% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- IPH Stock